A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer

By MacKenzie Mary   Hirte Holger   Glenwood Goss   Jean Maroun   Goel Rakesh   Major Pierre   Miller Jr. Wilson   Panasci Lawrence   Lorimer Ian   Batist Gerald   Matthews Sarah   Douglas Lynn   Seymour Lesley  

Investigational New Drugs, Vol. 23, Iss. 2, 2005-01 ,pp. : 165-170

Springer Publishing Company

Access to resources Recommend Favorite

ZD1839: targeting the epidermal growth factor receptor in cancer therapy

By Herbst Roy S  

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 6, 2002-06 ,pp. : 837-849

Informa Healthcare

Access to resources Recommend Favorite

A review of erlotinib – an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor

By Iyer Renuka   Bharthuar Anubha  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 2, 2010-02 ,pp. : 311-320

Informa Healthcare

Access to resources Recommend Favorite

Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor

By  

Clinical Pharmacology In Drug Development, Vol. 4, Iss. 2, 2015-03 ,pp. : 137-142

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers

By  

Clinical Pharmacology In Drug Development, Vol. 4, Iss. 2, 2015-03 ,pp. : 83-88

John Wiley & Sons Inc

Access to resources Recommend Favorite